Evidence map›Paper›PMID 23130652›Full record

ArticleClinical science (London, England : 1979)2013

Angiotensin-converting enzyme inhibition curbs tyrosine nitration of mitochondrial proteins in the renal cortex during the early stage of diabetes mellitus in rats.

Naohito Ishii, Pamela K Carmines, Masanori Yokoba, Hiroyuki Imaizumi, Tsuyoshi Ichikawa, Hideki Ikenagasa, Yoshio Kodera, Masamichi Oh-Ishi, Yoshikazu Aoki, Tadakazu Maeda and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Clinical science (London, England : 1979), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. The Ginsenoside RgLife (Basel, Switzerland) · 2021
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Naohito IshiiDepartment of Medical Laboratory Sciences, Kitasato University School of Allied Health Sciences, Kanagawa 252-0373, Japan.
Pamela K Carmines
Masanori Yokoba
Hiroyuki Imaizumi
Tsuyoshi Ichikawa
Hideki Ikenagasa
Yoshio Kodera
Masamichi Oh-Ishi
Yoshikazu Aoki
Tadakazu Maeda
Tsuneo Takenaka
Masato Katagiri
Kitasato University · JPSaitama Medical University · JPTochigi Medical Center · JPWacom (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Experiments were performed to evaluate the hypothesis that ACE (angiotensin-converting enzyme) inhibition (enalapril) suppresses 3-NT (3-nitrotyrosine) production in the renal cortex during the early stage of Type 1 DM (diabetes mellitus) in the rat. Enalapril was administered chronically for 2 weeks to subsets of STZ (streptozotocin)-induced DM and vehicle-treated sham rats. O(2)(-) (superoxide anion) and NO(x) (nitrate+nitrite) levels were measured in the media bathing renal cortical slices after 90 min incubation in vitro. SOD (superoxide dismutase) activity and 3-NT content were measured in the renal cortex homogenate. Renal cortical nitrated protein was identified by proteomic analysis. Renal cortical production of O(2)(-) and 3-NT was increased in DM rats; however, enalapril suppressed these changes. DM rats also exhibited elevated renal cortical NO(x) production and SOD activity, and these changes were magnified by enalapril treatment. 2-DE (two-dimensional gel electrophoresis)-based Western blotting revealed more than 20 spots with positive 3-NT immunoreactivity in the renal cortex of DM rats. Enalapril treatment blunted the DM-induced increase in tyrosine nitration of three proteins ACO2, GDH1 and MMSDH (aconitase 2, glutamate dehydrogenase 1 and methylmalonate-semialdehyde dehydrogenase), each of which resides in mitochondria. These data are consistent with enalapril preventing DM-induced tyrosine nitration of mitochondrial proteins by a mechanism involving suppression of oxidant production and enhancement of antioxidant capacity, including SOD activation.

Indexed as

Angiotensin-Converting Enzyme InhibitorsAnimalsDiabetes Mellitus, Type 1Disease Models, AnimalHumansKidney CortexMaleMitochondrial ProteinsPeptidyl-Dipeptidase ARatsRats, Sprague-DawleyTyrosine3-nitrotyrosineAngiotensin-Converting Enzyme InhibitorsMitochondrial ProteinsPeptidyl-Dipeptidase ATyrosine

Identifiers

PMID23130652
PMCPMC3540783
OpenAlexW2018333085

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.